AARP claims expanding IRA drug caps could spare Medicare $200 billion
AARP released a report saying that adding price controls to ten currently exempt medicines under the Inflation Reduction Act could save Medicare nearly $200 billion between 2029 and 2033.
The senior-advocacy group argues that Democrats should broaden the IRA’s drug-pricing provisions if they regain control of Congress and the White House. Its analysis focuses on ten popular drugs that are not subject to the existing caps. By extending limits to these medicines, the report projects Medicare would avoid close to $200 billion in spending over a five-year span. The estimate is intended to motivate lawmakers to act on the proposal.
Why it matters
The proposal could dramatically lower Medicare drug costs, affecting seniors and federal spending.
In this story
